TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02.
|
Departure of Directors or Certain Officers; Election of |
On December 19, 2016, the Compensation Committee of the Board of
Directors (the Compensation Committee) of TRACON Pharmaceuticals,
Inc. (the Company or TRACON) approved a bonus plan (the Bonus
Plan), which sets forth the terms of the annual incentive bonus
opportunity for eligible employees of the Company. Under the
Bonus Plan, the Companys executive officers are eligible to
receive bonus awards that are determined based on the achievement
of the Companys corporate goals for the applicable plan year and
an evaluation of individual performance measured against
pre-established individual performance goals for the applicable
plan year. Corporate goals for the 2016 plan year were previously
established on January 21, 2016.Bonuses, if any, under the Bonus
Plan will be payable in cash or equity, or a combination of both,
after the end of the applicable plan year and no later than
December 31 of the following year.
|
Item 9.01. |
Financial Statements and Exhibits. |
|
(d) |
Exhibits |
|
10.1 |
TRACON Pharmaceuticals, Inc. Bonus Plan. |
About TRACON Pharmaceuticals, Inc. (NASDAQ:TCON)
TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company’s lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Recent Trading Information
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) closed its last trading session down -0.15 at 4.75 with 63,643 shares trading hands.